Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$195.28
+2.4%
$187.10
$163.81
$218.66
$344.98B0.486.28 million shs3.66 million shs
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$7.34
+0.1%
$6.30
$4.02
$15.10
$399.07M2.091.71 million shs646,886 shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.80
-1.2%
$0.69
$0.53
$7.11
$128.16M0.32.56 million shs606,683 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$11.65
+11.1%
$10.19
$5.83
$26.25
$487.32MN/A188,220 shs183,038 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.60%-0.02%+0.85%+9.75%+13.46%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
+5.67%+2.68%+11.93%+70.46%-16.63%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
+6.56%+8.73%+37.23%-20.37%-87.27%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+5.22%+2.64%-12.00%+54.72%+1,048,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.7974 of 5 stars
2.45.03.33.94.01.71.3
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
4.2911 of 5 stars
3.51.00.04.62.02.51.3
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
4.6826 of 5 stars
4.15.00.03.41.10.81.9
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.2208 of 5 stars
3.50.00.00.00.60.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.81
Moderate Buy$211.298.20% Upside
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.00
Buy$14.3395.41% Upside
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.13
Hold$4.78501.68% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
3.00
Buy$36.67214.74% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, ZBIO, and EBS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$205.00
6/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$204.00
5/16/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$35.00
5/14/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$210.00 ➝ $205.00
5/8/2025
AbbVie Inc. stock logo
ABBV
AbbVie
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/29/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$214.00 ➝ $216.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.00
4/22/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$210.00
4/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$214.00 ➝ $214.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.12$15.36 per share12.71$1.90 per share102.78
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$1.04B0.38$2.05 per share3.58$8.91 per share0.82
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$351.41M0.37$0.05 per share15.26($1.88) per share-0.42
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$5M97.46N/AN/A$7.48 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.3583.1113.971.287.31%412.03%13.11%7/31/2025 (Estimated)
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$190.60M-$2.71N/A3.54N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$880K-$0.20N/A3.18N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$156.99M-$3.55N/AN/AN/AN/AN/A8/21/2025 (Estimated)

Latest IRWD, ABBV, ZBIO, and EBS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.21N/AN/AN/A$148.55 millionN/A
7/24/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24N/AN/AN/A$14.93 billionN/A
5/15/2025Q1 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million
5/7/2025Q1 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.49$0.71+$0.22$1.19$218.50 million$222.20 million
5/7/2025Q1 2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.36%N/A279.15%53 Years
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
N/AN/AN/AN/AN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A

Latest IRWD, ABBV, ZBIO, and EBS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/20/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.54%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.76
0.64
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20
6.32
3.51
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
3.34
3.34
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A
6.47
6.47

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
78.40%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
12.70%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.76 billionOptionable
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2,42054.28 million53.63 millionOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
220161.82 million141.27 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A41.83 million34.93 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$195.28 +4.66 (+2.44%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Emergent Biosolutions stock logo

Emergent Biosolutions NYSE:EBS

$7.34 +0.01 (+0.07%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.80 -0.01 (-1.16%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$11.65 +1.16 (+11.06%)
As of 03:33 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.